Bioject gets second deal with Amgen:
This article was originally published in Clinica
Executive Summary
Bioject Medical Technologies has formed a second agreement with Amgen for Bioject's needle-free injection system for certain of Amgen's therapeutics. Bioject will get $1 million upfront, as well as development milestones and other payments. Amgen will get exclusive rights to the Portland, Oregon-based company's modified B2000 needle-free system. Under the terms of the new contract, Amgen's potential use of the needle-free systems is expanded. It also includes product licensing and commercial supply terms. The initial contract was signed in March 2000 and covered Bioject's Iject systems.